Mosul University
  • Register
  • Login
  • العربیة

Iraqi Journal of Pharmacy

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 19, Issue 2
  3. Author

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Editorial Staff

Facts and Figures

Publication Ethics

Indexing and Abstracting

Peer Review Process

News

Guide to reviwers

Defining Pathological Iron Status in Children with Thalassemia

    Bashar Sh. Mustafa

Iraqi Journal of Pharmacy, 2022, Volume 19, Issue 2, Pages 108-116
10.33899/iphr.2022.176656

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

The purpose of this review is to summarize the recent knowledge that has been gathered, allowing a better understanding of iron status in children with thalassemia. Children with thalassemia major typically have severe anemia during the first two stages of life and receive regular red blood cell (RBC) transfusions. The results show that individuals with thalassemia major who are overtly or inadequately transfused have significant body changes that affect physical growth retardation, hostility, weak musculature, leg muscle fitness, extramedullary development of hematopoiesis, and bone expansion, as seen in some developing countries. Cases of thalassemia intermedia occur late and have mild anemia, and cannot tolerate regular blood transfusions. Treatment for thalassemia major includes regular red blood cell transfusions, iron chelating drugs, and bone marrow surgery. In addition, spleen scanning may be necessary in some cases. Also, a bone marrow transplant is the only definitive treatment currently available. The prognosis for patients with beta-thalassemia has improved most over the past 25 years, mostly due to recent medical advances in blood transfusions, iron-chelating drugs, and bone marrow transplants. However, heart disease (heart disease) has been found to remain the leading cause of death in iron-related cases.
Keywords:
    Thalassemia pediatric Iron Chelating agents Blood transfusion
  • PDF (784 K)
  • XML
(2022). Defining Pathological Iron Status in Children with Thalassemia. Iraqi Journal of Pharmacy, 19(2), 108-116. doi: 10.33899/iphr.2022.176656
Bashar Sh. Mustafa. "Defining Pathological Iron Status in Children with Thalassemia". Iraqi Journal of Pharmacy, 19, 2, 2022, 108-116. doi: 10.33899/iphr.2022.176656
(2022). 'Defining Pathological Iron Status in Children with Thalassemia', Iraqi Journal of Pharmacy, 19(2), pp. 108-116. doi: 10.33899/iphr.2022.176656
Defining Pathological Iron Status in Children with Thalassemia. Iraqi Journal of Pharmacy, 2022; 19(2): 108-116. doi: 10.33899/iphr.2022.176656
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 30
  • PDF Download: 44
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus